ArticleBiomaterials2012
Engineered phage-based therapeutic materials inhibit Chlamydia trachomatis intracellular infection.
Article in Biomaterials, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 72 citations in OpenAlex.
- Review
- Phage therapy for treatment of bacterial vaginosis.Archives of microbiology · 2026Review
- Biologic drug development for treatment and prevention of sexually transmitted infections.Clinical microbiology reviews · 2025Review
- Engineered bacteriophages for therapeutic and diagnostic applications.Disease models & mechanisms · 2025Review
- Leveraging the microbiome to combat antibiotic resistant gynecological infections.npj antimicrobials and resistance · 2025Review
- Cyanophage Engineering for Algal Blooms Control.Viruses · 2024Review
- Renewed insights into Ackermannviridae phage biology and applications.Npj viruses · 2024Review
- Efficient Broad-Spectrum Cyanophage Function Module Mining.Microorganisms · 2024Article
- RNA and Single-Stranded DNA Phages: Unveiling the Promise from the Underexplored World of Viruses.International journal of molecular sciences · 2023Review
- Engineered phage with cell-penetrating peptides for intracellular bacterial infections.mSystems · 2023Article
- Genetic Engineering and Biosynthesis Technology: Keys to Unlocking the Chains of Phage Therapy.Viruses · 2023Review
- Review
- Disarm The Bacteria: What Temperate Phages Can Do.Current issues in molecular biology · 2023Review
- Bacteriophages as Biotechnological Tools.Viruses · 2023Review
- Potential for Phages in the Treatment of Bacterial Sexually Transmitted Infections.Antibiotics (Basel, Switzerland) · 2021Review
- Engineered Bacteriophage Therapeutics: Rationale, Challenges and Future.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2021Review
- A combination therapy of Phages and Antibiotics: Two is better than one.International journal of biological sciences · 2021Review
- Engineered M13 Peptide Carrier Promotes Angiogenic Potential of Patient-Derived Human Cardiac Progenitor Cells and In Vivo Engraftment.Tissue engineering and regenerative medicine · 2020Article
- Approaches to optimize therapeutic bacteriophage and bacteriophage-derived products to combat bacterial infections.Virus genes · 2020Review
- Phage-mimicking antibacterial core-shell nanoparticles.Nanoscale advances · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
Abstract
Developing materials that are effective against sexually transmitted pathogens such as Chlamydia trachomatis (Ct) and HIV-1 is challenging both in terms of material selection and improving bio-membrane and cellular permeability at desired mucosal sites. Here, we engineered the prokaryotic bacterial virus (M13 phage) carrying two functional peptides, integrin binding peptide (RGD) and a segment of the polymorphic membrane protein D (PmpD) from Ct, as a phage-based material that can ameliorate Ct infection. Ct is a globally prevalent human pathogen for which there are no effective vaccines or microbicides. We show that engineered phage stably express both RGD motifs and Ct peptides and traffic intracellularly and into the lumen of the inclusion in which the organism resides within the host cell. Engineered phage were able to significantly reduce Ct infection in both HeLa and primary endocervical cells compared with Ct infection alone. Polyclonal antibodies raised against PmpD and co-incubated with constructs prior to infection did not alter the course of infection, indicating that PmpD is responsible for the observed decrease in Ct infection. Our results suggest that phage-based design approaches to vector delivery that overcome mucosal cellular barriers may be effective in preventing Ct and other sexually transmitted pathogens.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.